Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 6/20 | 0.57 |
| ▸ | NPFFR2 | Q9Y5X5 | 6/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295050 | 1.00 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6TSHRCYP3A4 | |
| SCHEMBL17606484 | 0.93 | NPFFR1 (0.61) | NPFFR1NPFFR2CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL1770778 | 0.91 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6TSHRCYP3A4 | |
| SCHEMBL13738215 | 0.91 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6TSHRCYP3A4 | |
| SCHEMBL31447501 | 0.89 | NPFFR1 (0.55) | NPFFR1NPFFR2CYP2D6TSHRCYP3A4 | |
| SCHEMBL27929854 | 0.89 | NPFFR1 (0.48) | NPFFR1NPFFR2PPIASIGMAR1 | |
| SCHEMBL27947092 | 0.89 | NPFFR1 (0.48) | NPFFR1NPFFR2PPIASIGMAR1 | |
| SCHEMBL24347013 | 0.88 | NPFFR1 (0.54) | NPFFR1NPFFR2CYP2D6TSHRCYP3A4 | |
| SCHEMBL15774951 | 0.88 | NPFFR1 (0.54) | NPFFR1NPFFR2CYP2D6TSHRCYP3A4 | |
| SCHEMBL6703813 | 0.86 | NPFFR1 (0.61) | NPFFR1NPFFR2CYP2D6CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678329-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8889704-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | NPFFR1 2024/4885NPFFR2 2070/4885CYP2D6 1089/4885 |
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | NPFFR1 1407/4885NPFFR2 2316/4885CYP2D6 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.